Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fund

Plus, news about Vyne Therapeutics, Prelude Therapeutics, Bausch Health and Minerva Neurosciences: 🏛️ Neurizon Therapeutics says FDA delayed IND decision: The biotech is still waiting to see if the regulator will ...